Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell

MT Newswires Live

Sep 19

Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.

The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.

Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.

Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568926350"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568926350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568926350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568926350","market":"us","top_or_hot":-1,"title":"Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-19 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568926350","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568926350","pubTimestamp":1758285308,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verrica Pharmaceuticals  said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Verrica表示开发合作伙伴获得日本对Ycanth的批准；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":1},"content_text":"Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}